Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan-Jun;43(1):13-19.
doi: 10.4103/ijstd.ijstd_2_21. Epub 2022 Jun 7.

Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review

Sivaraman Balaji  1 , J Madhumathi  1 , Aradhana Bhargava  2 , Tanvi Singh  1 , Nupur Mahajan  1 , Deepti Ambalkar  3 , Sumit Aggarwal  1
Affiliations

Patterns of human immunodeficiency virus drug resistance mutations in people living with human immunodeficiency virus in India: A scoping review

Sivaraman Balaji et al. Indian J Sex Transm Dis AIDS. 2022 Jan-Jun.

Abstract

The human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS) epidemic still exists as a major global public health burden, especially in the middle- and low-income countries. Antiretroviral therapy (ART) remains a sole option to reduce the mortality and morbidity associated with this disease as no approved vaccine candidates are available. About 67% of the people living with HIV (PLHIV) have received the ART in 2019 worldwide. As a consequence of increased ART regimes, the prevalence of drug resistance mutations (DRM) also has been escalating and it would become a significant barrier in achieving the United Nations Programme on HIV/AIDS goal of eliminating HIV by 2030. So far, nucleoside reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors (NNRTI), and protease inhibitor-(PI) associated DRM have been reported across the globe with a considerable escalation in the annual prevalence rate of pretreatment NNRTI DRM. Conversely, NRTI-associated DRM is still under 5%, with a few scattered reports of significant increase from few countries such as southern and eastern Africa. Likewise, in India, the propositions of NRTI and NNRTI-associated DRM have increased since the commencement of the nationwide ART program in 2004. In agreement to the global trend, M1841/V, a type of NNRTI, remains as a dominant DRM among PLHIV. In this review, we tried to collate various mechanisms of DRM in PLHIV. In addition, patterns of HIV DRM in India and their future challenges on drug-related mutations have been discussed.

Keywords: Drug resistance mutations; nonnucleoside reverse transcriptase inhibitors; nucleoside reverse transcriptase inhibitors; people living with human immunodeficiency virus; protease inhibitor.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
PRISMA flow diagram. Presentation of the procedure of literature searching and selection with number of articles at each stage
Figure 2
Figure 2
Mechanism of anti-HIV drugs NRTIs and NNRTIs
Figure 3
Figure 3
HIV Protease Inhibitor mechanism
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Fanales-Belasio E, Raimondo M, Suligoi B, Buttò S. HIV virology and pathogenetic mechanisms of infection: A brief overview. Ann Ist Super Sanita. 2010;46:5–14. - PubMed
    1. UNAIDS. 2019. Archived from the Original on December 4, 2019. [Last accessed on 2019 Dec 21]. https://www.unaids.org/en/resources/documents/2019/2019- UNAIDS-data.
    1. National AIDS Control Organization (NACO) and National Institute of Medical Statistics (ICMR). India HIV Estimations 2017. Technical Report. [Last accessed on 2021 Dec 24]. Available from: http://naco.gov.in/sites/default/files/Fact%20 Sheets.pdf .
    1. Kemnic TR, Gulick PG. Stat Pearls. Treasure Island (FL): Stat Pearls Publishing; 2020. HIV Antiretroviral Therapy. Available from: https://www.ncbi.nlm.nih.gov/books/NBK513308/ - PubMed
    1. World Health Organization. 2nd ed. Geneva: World Health Organization; 2017. [Lastaccessed on 2020 October 11]. Guidelines for Managing Advanced HIV Disease and Rapid Initiation of Antiretroviral Therapy. Recommendations for Public Health Approach; p. 422. Available from: https://www.who.int/hiv/pub/toolkits/ advanced-HIV-disease-policy/en/ - PubMed

Publication types